Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04672239 · ClinicalTrials.gov registry record · NA

A Proof-of-concept RCT of Version 3.0 of the Smoking Cessation Smartphone App "Smiling Instead of Smoking" (SiS)

A NA study, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
229
Enrollment target

NCT04672239: Completed NA study, sponsored by Massachusetts General Hospital.

NCT04672239 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 229 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04672239, a NA study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
229 participants
Enrollment target

Study Summary

This is the third study in a series of 3 studies to develop a smartphone app to support nondaily smokers in quitting smoking, as funded by the American Cancer Society grant #RSG CPPB - 130323 (project dates: 07/01/2017 - 6/30/2021). Study 1 (2017P001106) demonstrated feasibility and acceptability when smokers were onboarded in person. Study 2 (2018P002699) demonstrated feasibility and acceptability when smokers were onboarded remotely, nationwide. The present study is Study 3. It is a 3-group proof-of-concept RCT, in which we seek to test if our app (i.e., Version 3 of our developed smartphone app, called 'Smiling instead of Smoking' (SiS)) is superior to treatment as usual (i.e., TAU) and superior to a control app (i.e., the National Cancer Institute's smartphone app "QuitGuide" (QG).

Primary Outcome

The Smoking Self-Efficacy Questionnaire (SEQ-12) (Etter, Bergman, Humair, \& Perneger, 2000) is a two-dimensional 12-item self-report scale measuring a person's confidence in his or her ability to abstain from smoking when facing internal stimuli (e.g. feeling depressed) and external stimuli (e.g. being with smokers) on a 0-100 slider scale (i.e., 0=not at all confident that I can refrain; 100=extremely confident that I can refrain). Scale scores are created by mean scoring across items and rang

Interventions

  • BEHAVIORAL Smartphone app "Smiling instead of Smoking" (SiS) Version 3
  • BEHAVIORAL Smartphone app "QuitGuide" (QG)
  • BEHAVIORAL Brochure "Clearing the Air" (CTA)

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2021-01-28
Est. Completion 2023-01-06
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT04672239 record still lists

NCT04672239 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 3 interventions - of which Smartphone app "Smiling instead of Smoking" (SiS) Version 3 is the first listed.

NCT04672239 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04672239 about?

NCT04672239 is a clinical study titled "A Proof-of-concept RCT of Version 3.0 of the Smoking Cessation Smartphone App "Smiling Instead of Smoking" (SiS)". This is the third study in a series of 3 studies to develop a smartphone app to support nondaily smokers in quitting smoking, as funded by the American Cancer Society grant #RSG CPPB - 130323 (project dates: 07/01/2017 - 6/30/2021). Study 1 (2017P001106) demonstrated feasibility and acceptability wh...

What is the current status of trial NCT04672239?

This trial is currently completed. It is a NA study. The enrollment target is 229 participants. The study started on 2021-01-28. Estimated completion is 2023-01-06.

What interventions are being tested in trial NCT04672239?

The interventions under investigation include: Smartphone app "Smiling instead of Smoking" (SiS) Version 3 (BEHAVIORAL), Smartphone app "QuitGuide" (QG) (BEHAVIORAL), Brochure "Clearing the Air" (CTA) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04672239?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04672239's enrollment target sits among peer trials

229 468th of 2000 higher than 1,533 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04672239, the US trial registry maintained by the National Library of Medicine. NCT04672239 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.